FDA Grants Priority Review For Schering-Plough’s Peginterferon Alfa 2b For The Adjuvant Treatment Of Patients With Stage III Melanoma

Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) has accepted the Peg-IFN (peginterferon alfa-2b) supplemental Biologics License Application (sBLA) for review and has granted Priority Review status for the adjuvant treatment of patients with Stage III melanoma. Schering-Plough submitted its application to the agency in the fall of 2007.

More: continued here

Filed under: Dermatology on February 7th, 2008